EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PD-L1 testing by immunohistochemistry in immuno-oncology

Semir Vranic, Zoran Gatalica

Biomolecules and Biomedicine · 06.01.2023 · 23 (1) · 15-25

DOI: 10.17305/bjbms.2022.7953 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 06.01.2023. Verfasst von Semir Vranic und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, QU Health, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 77-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. However, only ~30% of patients benefit from immune checkpoint inhibitors. Tumor PD-L1 expression, assessed by immunohistochemistry, is the most widely validated and used predictive biomarker to guide the selection of patients for immune checkpoint inhibitors. PD-L1 assessment may be challenging due to the necessity for different companion diagnostic assays for required specific immune checkpoint inhibitors and a relatively high level of inter-assay variability in terms of performance and cutoff levels. In this review, we discuss the role of PD-L1 immunohistochemistry as a predictive test in immunotherapy (immuno-oncology), highlight the complexity of the PD-L1 testing landscape, discuss various preanalytical, analytical and clinical issues that are associated with PD-L1 assays, and provide some insights into optimization of PD-L1 as a predictive biomarker in immuno-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsHumansImmune Checkpoint InhibitorsImmunohistochemistryMedical Oncology

Substanzen

B7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • College of Medicine, QU Health, Qatar University, Doha, Qatar.
  • Department of Pathology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States.

Zitieren

APA

Vranic, S., & Gatalica, Z. (2023). PD-L1 testing by immunohistochemistry in immuno-oncology. Biomolecules and Biomedicine, 23(1), 15-25. https://doi.org/10.17305/bjbms.2022.7953

Vancouver

Vranic S, Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomolecules and Biomedicine. 2023;23(1):15-25. doi:10.17305/bjbms.2022.7953

BibTeX
@article{Vranic2023,
  author = {Vranic, Semir and Gatalica, Zoran},
  title = {PD-L1 testing by immunohistochemistry in immuno-oncology},
  journal = {Biomolecules and Biomedicine},
  year = {2023},
  volume = {23},
  number = {1},
  pages = {15--25},
  doi = {10.17305/bjbms.2022.7953}
}
Kostenlos starten →